Sanofi, Regeneron: 18-Month Results of ODYSSEY LONG TERM Trial with Praluent Published in The New England Journal of Medicine Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent Published in The New England Journal of Medicine - Robust and consistent LDL-C lowering demonstrated with PraluentTM in largest, double-blind, placebo-controlled trial of a PCSK9 inhibitor to date - - Fewer major cardiovascular events observed with PraluentTM in post hoc analysis - PARIS and TARRYTOWN, N.Y., March 15, 2015 -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that 18-month results of a Phase 3 trial of Praluent , an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New England Journal of Medicine .
http://ift.tt/1GStreg
http://ift.tt/1GStreg
No comments:
Post a Comment